Bioconjugate Chemistry · 2016 · 45 citations · 28 references
MedicineMolecular BiologyNuclear MedicineMolecular ImagingProtein EngineeringTherapeutic Nuclear MedicineLigand BindingProtein Scaffold EngineeringRadiopharmaceuticalsScaffold ProteinsTherapeutic Protein EngineeringBindersPeptide RadiolabelingPeptide-based ProbesPeptide-based RadiopharmaceuticalsProtein-based Imaging AgentsPurificationRadioligand ImagingRadionuclide Labeling
Engineered scaffold proteins (ESP) are high-affinity binders that can be used as probes for radionuclide imaging. Histidine-containing tags enable both efficient purification of ESP and radiolabeling with (99m)Tc(CO)3. Earlier studies demonstrated that the use of a histidine-glutamate-histidine-glutamate-histidine-glutamate (HE)3-tag instead of the commonly used hexahistidine (H6)-tag reduces hepatic uptake of radiolabeled ESP and short peptides. Here, we investigated the influence of histidine-containing tags on the biodistribution of a novel type of ESP, ADAPTs. A series of anti-HER2 ADAPT probes having H6- or (HE)3-tags in the N-termini were prepared. The constructs, (HE)3-ADAPT6 and H6-ADAPT6, were labeled with two different nuclides, (99m)Tc or (111)In. The labeling with (99m)Tc(CO)3 utilized the histidine-containing tags, while (111)In was attached through a maleimido derivative of DOTA conjugated to the N-terminus. For (111)In-labeled ADAPTs, the use of (HE)3 provided a significantly (p < 0.05) lower hepatic uptake at 1 h after injection, but there was no significant difference in hepatic uptake of (111)In-(HE)3-ADAPT6 and H6-ADAPT6 at later time points. Interestingly, in the case of (99m)Tc, (99m)Tc(CO)3-H6-ADAPT6 provided significantly (p < 0.05) lower uptake in a number of normal tissues and was more suitable as an imaging probe. Thus, the influence of histidine-containing tags on the biodistribution of the novel ADAPT scaffold proteins was different compared to its influence on other ESPs studied so far. Apparently, the effect of a histidine-containing tag on the biodistribution is highly dependent on the scaffold composition of the ESP.
28
Targeted Radionuclide Therapy with A <sup>177</sup>Lu-labeled Anti-HER2 Nanobody
Matthias D’Huyvetter, Cécile Vincke, Catarina Xavier et al. · Theranostics · 2014 · 221 citations · Full text
Medicine, Nuclear Medicine, Oncology +17
Sara Ahlgren, Helena Wållberg, Thuy Tran et al. · Journal of Nuclear Medicine · 2009 · 113 citations · Full text
Medicine, Biochemistry, Oncology +17